EXPERIMENTAL STUDY

The role of CXCR5 and its ligand CXCL13 in the compartmentalization of lymphocytes in thyroids affected by autoimmune thyroid diseases

G Aust, D Sittig, L Becherer, U Anderegg, A Schütz, P Lamesch and E Schmücking

Institute of Anatomy, 1Department of Surgery, 2Department of Dermatology and 3Institute of Pathology, University of Leipzig, Leipzig, Germany

(Correspondence should be addressed to G Aust, University of Leipzig, Institute of Anatomy, Ph-Rosenthal-Strasse 55, Leipzig, 04103, Germany; Email: ausg@medizin.uni-leipzig.de)

Abstract

Objective: Graves' disease (GD) and Hashimoto's thyroiditis (HT) are characterized by lymphocytic infiltrates partly resembling secondary lymphoid follicles in the thyroid. CXCR5 and its ligand CXCL13 regulate compartmentalization of B- and T-cells in secondary lymphoid organs. The aim of the study was to elucidate the role of this chemokine receptor–ligand pair in thyroid autoimmunity.

Methods: Peripheral blood and thyroid-derived lymphocyte subpopulations were examined by flow cytometry for CXCR5. CXCR5 and CXCL13 cDNA were quantified in thyroid tissues by real-time RT-PCR.

Results: We found no differences between the percentages of peripheral blood CXCR5+ T- and B-cells in GD patients (n = 10) and healthy controls (n = 10). In GD patients, the number of memory CD4+ cells expressing CXCR5 which are functionally characterized as follicular B helper T-cells is higher in thyroid-derived (18 ± 3%) compared with peripheral blood T-lymphocytes (8 ± 2%). The highest CXCL13 mRNA levels were found in HT (n = 2, 86.1 ± 1.2 zmol (10^-21 mol) cDNA/PCR) followed by GD tissues (n = 16, 9.6 ± 3.5). Only low amounts were determined in thyroid autonomy (TA) (n = 11) thyroid tissues, irrespective of whether the autonomous nodule (0.5 ± 0.1) or the surrounding normal tissue (1.8 ± 0.7) had been analyzed. The same differences were found for CXCR5 (HT: 179.1 ± 6.8; GD: 17.4 ± 10.6; TA[nodule]: 0.8 ± 0.5; TA[normal]: 4.4 ± 3.6). In GD, there is a correlation between CXCL13 and CXCR5 mRNA levels and the number of focal lymphocytic infiltrates and germinal centers as well as anti-thyroperoxidase but not anti-TSH receptor autoantibodies.

Conclusions: CXCR5 and CXCL13 play an essential role in maintaining B- and T-cells in lymphocytic infiltrates and ectopic follicles in thyroid tissue from patients affected by autoimmunity.

European Journal of Endocrinology 150 225–234

Introduction

Lymphoid follicles are usually observed in secondary lymphoid tissues and organs, and are essential structures for normal immune responses in which antigen-specific B- and T-cells are expanded against antigens. Chemokines and their receptors are involved in compartmentalization of these follicles establishing spatially and functionally segregated microenvironments. The role of CXCR5 and its unique ligand CXCL13 (BCA-1; B-cell attracting chemokine 1) in the organization of lymphoid follicles is clearly demonstrated in gene-targeted mice (1–3). Interaction between CXCR5 and CXCL13 is especially required for B-cell architectural organization (4). In CXCL13-deficient mice, B-cells failed to organize in polarized follicular clusters and instead appeared as a ring of cells at the perimeter of T-cell areas.

Naive B-cells localize in a CXCR5-dependent manner in the B-cell zone of the normal lymphoid follicle where CXCL13 is produced by stromal cells mainly representing follicular dendritic cells. In addition to B-cells, CXCR5 is expressed in a subset of memory CD4+ T-cells termed follicular B-helper T-cells (Tfh) that migrate into the B-cell zone to support immunoglobulin production (5–8).

In addition to lymphoid follicles located in secondary lymphoid tissues and organs, follicle formation is observed ectopically in chronic inflammatory sites or tissues affected by autoimmunity. Here, they recapitulate the structure of normal secondary follicles. Ectopic lymphoid follicles have been demonstrated in synovium from chronic arthritis patients (9, 10), in the salivary gland from patients with Sjögren’s syndrome (11), and in intestinal specimens from patients with colitis ulcerosa (12). CXCL13 and CXCR5 are expressed in these irregular aggregates, suggesting that both may play a role in aberrant lymphoid tissue.

In autoimmune thyroid diseases, ectopic lymphoid follicles have been demonstrated in thyroid tissues from patients with Hashimoto’s thyroiditis (HT) as well as Graves’ disease (GD). Lymphocytic infiltration...
progressively replaces thyroid follicles in HT. A spectrum
of lymphocytic infiltration is observed in GD from the
minimal numbers of immune cells in some thyroids
(diffuse infiltration) to focal thyroiditis in others (13).
In contrast to HT, most of the thyroid in GD remains
intact except for signs of hyperfunction. In most cases,
there is a direct relationship between the extent of lympho-
cytic infiltration in GD tissues and the percentage of
germinal center (GC) formation. The degree of lympho-
cytic infiltration was related to the titers of anti-thyrogi-
bulin and anti-thyroperoxidase (TPO) antibodies (13).
T-cells were mostly scattered individually or in small
groups between the follicles; however, they mainly
formed clusters in the severely infiltrated group (14).
Recent studies suggest that chemokines and their
receptors are not only involved in the initiation and
maintenance of the autoimmune process in HT and
GD (15–18), but are also capable of organizing and
sustaining lymphoid follicles in the thyroid (17, 19).
Armengol et al. (17) detected CXCL13 mRNA in thy-
roids affected by autoimmunity, but not in normal thy-
roid. We published the first quantitative results on
CXCL13 mRNA levels in autoimmune and non-auto-
immune thyroid tissues (20), which were very recently
confirmed by others (19). All studies have shown that
the presence of chemokines in most thyroids is largely
restricted to lymphocytic cell infiltration. However,
thyrocytes and thyroid-derived fibroblasts are also
able to express some chemokines (21–25), and may
thus perturb the immune process.
The aim of our study was to evaluate whether any
difference in CXCR5 expression between thyroid-derived
lymphocytes (TLs) and peripheral blood lymphocytes
(PBLs) within memory CD4+ and CD8+ T-cell and
B-cell fractions had occurred. Moreover, we clarified the
question of whether intrathyroidal CXCR5 and
CXCL13 mRNA levels were correlated with the presence
and extension of focal lymphocytic infiltration in thy-
roids affected by GD and HT. In contrast to Armengol
et al. (19), who included multinodular goiter tissues as
controls, we compared the results with thyroid tissue from patients with non-autoimmune thyroid
autonomy (TA). TA nodules, nearly completely free of
any lymphocyte, are a useful background control; normal,
nodule-surrounding TA tissues mimic the normal thyroid situation. In addition to Armengol
et al. (19), we also quantified CXCR5 mRNA levels as
an extent of the number of CXCR5+ cells.
Our results demonstrated that CXCR5 and its ligand
are indeed involved in the organization and extension
of lymphocytic infiltrates and ectopic follicles.

Materials and methods
Patients
GD (n = 16, all females, mean age ± S.E.M. 35.6 ± 3.7
years), HT (n = 2, both females, 18 and 34 years)
and TA (n = 11, five females, 55.7 ± 5.2 years) were
diagnosed on the basis of clinical, biochemical and
immunological characteristics and from scintiscans
(Table 1). Thyroid scans using Tc-99m pertechnetate
from all patients with unifocal TA showed a single
hot nodule and a low uptake in the rest of the thyroid.
Hyperthyroidism was confirmed by measurements of
serum thyroid-stimulating hormone (TSH), free thyrox-
ine and free triiodothyronine. The diagnosis of GD was
also made on a clinical basis, which included the
presence of anti-thyroid antibodies, goiter and typical
symptoms and signs of thyrotoxicosis. The diagnosis
was confirmed by histopathological diagnosis. All GD
patients had been treated with anti-thyroid drugs
since diagnosis (Table 1).
Antibodies against TSH receptor (TSH-R) (TSH-bind-
ing-inhibiting immunoglobulin, TBII) and TPO were
measured in serum obtained up to 2 weeks before oper-
ation using commercial RIA kits (TRAKhuman DYNO-
TEST, anti-TPO, DYNOTEST; Brahms Diagnostica
GmbH, Berlin, Germany). All GD patients showed
positive TBII (> 2 IU/l), and 9 out of 16 showed positive
anti-TPO antibodies (> 60 U/ml). PBLs of GD patients
were investigated prior to surgery. Ten out of the
sixteen patients were selected for flow cytometry
studies. GD patients with low lymphocytic infiltration
and low or negative TPO antibody levels are rare.
Thyroid tissues from such patients were taken from
our established thyroid tissue bank. Because we
needed freshly isolated PBLs and TLs for flow
cytometry analysis, the ten other GD patients were
included in the present study when they underwent
surgery.
Peripheral blood samples from ten normal adults
(two male, eight female; mean age 33.7 ± 2.7 years)
without any history of autoimmune disease were used
as controls. The study was approved by the local Com-
mittee of Medical Ethics, and all patients gave their
written consent.

Real-time PCR
Total cellular RNA was isolated using the QIAGEN total
RNA isolation kit (QIAGEN GmbH, Hilden, Germany).
cDNA was synthesized from 1 µg RNA in a 20 µl stan-
ard reaction mixture containing 200 U Superscript II
RNaseH reverse transcriptase (Invitrogen GmbH,
Karlsruhe, Germany).
Quantitative PCR was performed on a Rotorgene
(Corbett Research, Mortlake, Australia) real-time
machine by using SYBR Green I (Molecular Probes
Europe. Leiden, The Netherlands) as a double-strand
DNA-specific binding dye and continuous fluorescence
monitoring. Amplification was carried out in a total
volume of 20 µl containing 0.5 µmol/l of each primer,
2.5 mmol/l MgCl2, 1.0 Taq Polymerase (Roche), 10 ×
Taq buffer (500 mmol/l KCl, 100 mmol/l Tris–HCl,
ph 8.3; Roche), 2 mmol/l of each dNTP, 1 µl 1:2000
Table 1  Sex, age, diagnosis, duration of GD (only GD patients) until enrollment, signs of GO (only GD patients), treatment with anti-thyroid drugs and thyroid histology of patients with GD, HT and TA. In GD the duration of anti-thyroid drug treatment is nearly identical with the duration of the disease.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Diagnosis</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Duration of disease (months)</th>
<th>Anti-thyroid drug treatment</th>
<th>Signs of GO</th>
<th>Number of focal infiltrates</th>
<th>Number of GCs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>GD</td>
<td>31</td>
<td>F</td>
<td>≥ 15</td>
<td>Yes</td>
<td>Yes</td>
<td>a</td>
<td>33</td>
</tr>
<tr>
<td>2</td>
<td>GD</td>
<td>29</td>
<td>F</td>
<td>≥ 15</td>
<td>Yes</td>
<td>Yes</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>GD</td>
<td>49</td>
<td>F</td>
<td>≤ 5</td>
<td>Yes</td>
<td>Yes</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>GD</td>
<td>29</td>
<td>F</td>
<td>≤ 5</td>
<td>Yes</td>
<td>No</td>
<td>13</td>
<td>10</td>
</tr>
<tr>
<td>5</td>
<td>GD</td>
<td>30</td>
<td>F</td>
<td>≤ 5</td>
<td>Yes</td>
<td>No</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>GD</td>
<td>48</td>
<td>F</td>
<td>≥ 15</td>
<td>Yes</td>
<td>Yes</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>7</td>
<td>GD</td>
<td>51</td>
<td>F</td>
<td>≥ 15</td>
<td>Yes</td>
<td>Yes</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>GD</td>
<td>14</td>
<td>F</td>
<td>≤ 5</td>
<td>Yes</td>
<td>No</td>
<td>22</td>
<td>6</td>
</tr>
<tr>
<td>9</td>
<td>GD</td>
<td>17</td>
<td>F</td>
<td>≥ 15</td>
<td>Yes</td>
<td>No</td>
<td>30</td>
<td>4</td>
</tr>
<tr>
<td>10</td>
<td>GD</td>
<td>69</td>
<td>F</td>
<td>≤ 5</td>
<td>Yes</td>
<td>No</td>
<td>15</td>
<td>4</td>
</tr>
<tr>
<td>11</td>
<td>GD</td>
<td>36</td>
<td>F</td>
<td>≥ 15</td>
<td>Yes</td>
<td>No</td>
<td>29</td>
<td>0</td>
</tr>
<tr>
<td>12</td>
<td>GD</td>
<td>36</td>
<td>F</td>
<td>≤ 5</td>
<td>Yes</td>
<td>Yes</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>13</td>
<td>GD</td>
<td>18</td>
<td>F</td>
<td>≥ 15</td>
<td>Yes</td>
<td>Yes</td>
<td>60</td>
<td>50</td>
</tr>
<tr>
<td>14</td>
<td>GD</td>
<td>25</td>
<td>F</td>
<td>≤ 15</td>
<td>Yes</td>
<td>Yes</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>15</td>
<td>GD</td>
<td>38</td>
<td>F</td>
<td>≤ 5</td>
<td>Yes</td>
<td>Yes</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>16</td>
<td>GD</td>
<td>50</td>
<td>F</td>
<td>≥ 15</td>
<td>Yes</td>
<td>No</td>
<td>12</td>
<td>1</td>
</tr>
<tr>
<td>17</td>
<td>HT</td>
<td>34</td>
<td>F</td>
<td>—</td>
<td>No</td>
<td>—</td>
<td>— a</td>
<td>68</td>
</tr>
<tr>
<td>18</td>
<td>HT</td>
<td>18</td>
<td>F</td>
<td>—</td>
<td>No</td>
<td>—</td>
<td>— a</td>
<td>90</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient</th>
<th>Diagnosis</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Duration of disease (months)</th>
<th>Anti-thyroid drug treatment</th>
<th>Signs of GO</th>
<th>Number of focal infiltrates</th>
<th>Number of GCs</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>TA</td>
<td>58</td>
<td>M</td>
<td>—</td>
<td>Yes</td>
<td>—</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>20</td>
<td>TA</td>
<td>52</td>
<td>F</td>
<td>—</td>
<td>No</td>
<td>—</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>21</td>
<td>TA</td>
<td>70</td>
<td>M</td>
<td>—</td>
<td>No</td>
<td>—</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>22</td>
<td>TA</td>
<td>44</td>
<td>M</td>
<td>—</td>
<td>No</td>
<td>—</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>23</td>
<td>TA</td>
<td>75</td>
<td>M</td>
<td>—</td>
<td>No</td>
<td>—</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>24</td>
<td>TA</td>
<td>38</td>
<td>F</td>
<td>—</td>
<td>Yes</td>
<td>—</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>25</td>
<td>TA</td>
<td>77</td>
<td>F</td>
<td>—</td>
<td>Yes</td>
<td>—</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>26</td>
<td>TA</td>
<td>74</td>
<td>M</td>
<td>—</td>
<td>Yes</td>
<td>—</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>27</td>
<td>TA</td>
<td>61</td>
<td>M</td>
<td>—</td>
<td>Yes</td>
<td>—</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>28</td>
<td>TA</td>
<td>35</td>
<td>F</td>
<td>—</td>
<td>Yes</td>
<td>—</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>29</td>
<td>TA</td>
<td>29</td>
<td>F</td>
<td>—</td>
<td>Yes</td>
<td>—</td>
<td>0</td>
<td>4</td>
</tr>
</tbody>
</table>

*a Lymphocytic infiltrates replaced the normal thyroid tissue almost completely.
SYBR Green I dissolved in DMSO and 1 μl 1:5 diluted cDNA.

The PCR primers were CXCR5 sense (5'-tac ccg cta aacg ctt ga atg gac-3'), antisense (5'-cag gcc aag ggg caa gat gaa gac-3'), CXCL13 sense (5'-ggc gca gat gga act tga gc-3') and antisense (5'-ctg ggg atc ttc gaa tgc ta-3'), or CD18 sense (5'-ggc gca cct gtc tga aaa caa-3') and antisense (5'-agc gcc atg aca aac gac tg-3') respectively. CD18 mRNA was measured in order to quantify leukocytic infiltration (24). Sizes of PCR products were: CXCR5 318 bp; CXCL13 158 bp and CD18 372 bp. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcripts were measured using a ready-to-use quantitative PCR test kit (Roboscreen Gesellschaft für Molekulare Biotechnologie, Leipzig, Germany) as previously described (26).

The PCR reactions were cycled 40 times after initial denaturation (95 °C, 2 min) with the following parameters: denaturation 95 °C, 10 s; annealing 60–68 °C, 20 s; extension 72 °C, 30 s. Control reactions for product identification consisted of (i) determining the length of the PCR products by visualization after agarose gel electrophoresis and ethidium bromide staining and (ii) analyzing the melting peaks in comparison with external standards in the PCR machine. The temperature at which all non-specific product had disappeared was determined by melting temperature analysis. The fluorescence signal from SYBR Green I was reduced to background levels at a temperature of 86 °C. In contrast, there was still a high level of SYBR Green I fluorescence at a temperature of 86 °C in the sample that contained a cDNA template. A melting-temperature profile was performed for all specific cDNAs and showed an almost identical pattern of melting. Consequently, a temperature of 86 °C was selected as the optimum for CXCR5, CXCL13 and CD18 cDNA.

External cDNA standards were constructed by cloning of PCR fragments into pGEM-T vector (Promega, Mannheim, Germany). The PCR fragments were generated by RT-PCR with the same primers as described above. Ligated fragments were transformed into JM-109-competent cells, and plasmid DNA was prepared by using the Plasmid Mini Kit (Qiagen, Hilden, Germany). Concentrations of standards were determined by measuring the OD at 260 nm. Amounts were calculated from a reference curve obtained from the simultaneously processed standard curve. Data are expressed as zeptomol (zmol; 10^{-21} mol) cDNA per attomol (10^{-18} mol) of GAPDH cDNA, which was calculated from the same cDNA sample.

Identification of lymphocytic infiltrates and GCs

Paraffin sections stained with hematoxylin and eosin (HE) were screened for focal lymphocytic infiltration. An infiltrate was defined as an accumulation of lymphocytes taking up more than 0.1 mm² at a thyroid section. GCs were identified in HE sections by their typical architecture and confirmed by staining for CD23, a marker of a subpopulation of follicular dendritic cells (27). The number of focal lymphocytic infiltrates and GCs was counted within an area of 226 mm².

Isolation of cell populations

PBLs were isolated using Ficoll density gradient centrifugation. Thyroid samples were obtained during the operation. Fat and connective tissue were removed immediately. TLs were isolated after mechanical disaggregation of the tissue in PBS. Free cells were subjected to Ficoll density gradient centrifugation.

Chemokine receptor analysis in flow cytometry

Directly fluorochrome-labeled monoclonal antibodies were supplied by R&D Systems GmbH Wiesbaden, Germany (CXCR5-PE, CCR7-PE, CD4-FITC, CD8-FITC), BD Biosciences Europe, Heidelberg, Germany (CD4-Cy-Chrome, CD8-PerCP, CD19-PerCP, CD45RO-FITC, CD62L-FITC), and DakoCytomation GmbH, Hamburg, Germany (CD3-RPE/Cy5).

TLs or PBLs (3 x 10⁵) were incubated with monoclonal antibodies for two- or three-color staining at the desired concentration for 25 min at 4 °C. The following combinations of monoclonal antibodies were used: (i) CXCR5-PE, CD3-RPE/Cy5, CD8-FITC or CD4-FITC, (ii) CXCR5-PE, CD3-RPE/Cy5 or CD8-PerCP or CD4-Cy-Chrome, CD45RO-FITC, (iii) CXCR5-PE, CD3-RPE/Cy5 or CD19-PerCP, CD62L-FITC, and (iv) CCR7-PE, CD3-PerCP/Cy5, CD62L-FITC. The cells were washed three times in PBS/1% fetal calf serum/0.1% sodium azide and analyzed by flow cytometry (FACScanners: Becton Dickinson, Mountain View, CA, USA) using electronic gating on lymphocytes (in some experiments by gating on CD3⁺, CD4⁺ or CD8⁺ lymphocytes) and compensation. Isotype-matched directly labeled irrelevant monoclonal antibodies (Dako) were used as negative controls; 15 000 cells over the forward-scatter threshold were analyzed.

Immunohistology

Frozen thyroid tissue samples were sectioned and fixed in 2% paraformaldehyde for 10 min at 4 °C. Endogenous peroxidase was quenched in 0.3% H₂O₂/methanol for 30 min. Non-specific antibody-binding sites were blocked with 3% normal goat serum for 20 min. Next, the CD23 monoclonal antibody (Dako) was applied to tissue sections for 1 h at room temperature. Subsequently, biotinylated goat anti-mouse IgG and streptavidin-peroxidase (Vector Laboratories, Inc, Burlingame, CA, USA) were added in sequence. Diaminobenzidine (Vector) was used as the chromogen.
Statistics
The comparison between the groups was performed using the Mann–Whitney test. Unless otherwise stated, the data are expressed as means ± S.E.M. The Spearman test was used for correlation analysis.

Results
Lymphocytic infiltrates and GCs within thyroid tissues
A high degree of cellular organization is acquired by the tissue-infiltrating lymphocytes in HT and GD. In GD thyroids, T- and B-cells are seldom arranged as diffuse infiltrates without specific microstructures (Fig. 1A). In most GD thyroids, B- and T-cells formed clusters, referred to here as focal lymphocytic infiltrates, lacking GCs (Fig. 1B). The number of these lymphocytic infiltrates varied significantly between the various patient groups (number/226 mm²; mean ± S.E.M.): GD tissues 14 ± 4, TA normal tissues 2 ± 1; TA nodular tissues no lymphocytic infiltrates. The number of lymphocytic infiltrates within normal TA tissue seems to represent the normal background reaction. Lymphocytes were abundant in the two HT tissues (Fig. 1D). In these HT thyroids and a subgroup of GD thyroids (10 out of 16), the autoimmune process additionally induces the formation of GCs that were easily identified in HE- and CD23-stained sections (Fig. 1C–E). GCs were found only in one TA tissue.

A subpopulation of follicular dendritic cells was identified by immunohistological staining for CD23 (27). Tissues with lymphocytic infiltrates without CD23⁺ follicular dendritic cells lacked GCs, indicating that these structures were different from primary follicles. The selective presence of CD23⁺ follicular

Figure 1 Pattern of lymphoid organization in thyroids affected by GD and HT. (A) Lymphocytes were diffusely distributed throughout the thyroid (arrows) in few GD patients. (B) We found formed focal lymphocytic infiltrates lacking GC reactions in most GD tissues. (C) Ectopic follicles with typical GCs (arrow) had formed in a subset of GD patients (10 out of 16). (D) In HT, thyroid tissues were often replaced by many large ectopic follicles. (E) CD23 characterizes a subpopulation of follicular dendritic cells located in GCs (HT patient). Scale bar 100 μm.
dendritic cells in GCs indicated that these cells are not a regular component of the thyroid tissue.

For further analysis, GD patients were divided into two groups according to the number of focal lymphocytic infiltrates (high: >5/226 mm²; low: ≤5/226 mm²) and the number of GCs (with/without).

**CXCR5 mRNA levels in thyroid tissues (Fig. 2)**

All thyroid tissues of HT and GD patients investigated were CXCR5- and CXCL13 mRNA-positive, while we frequently failed to obtain any signal, especially from thyroid nodule samples from TA patients. CXCR5 mRNA levels strongly correlated with the number of focal lymphocytic infiltrates and GCs, weakly with TPO, but not with TBI antibodies in GD (Table 2).

The highest CXCR5 mRNA levels were determined in thyroid tissues from the two HT patients (172.4 and 185.9 zmol CXCR5 cDNA/PCR) who also showed the highest numbers of lymphocytic infiltrates and GCs.

GD patients with high numbers of lymphocytic infiltrates (>5/226 mm²) showed a significantly higher CXCR5 mRNA level (zmol CXCR5 cDNA/PCR, mean±S.E.M. 36.3±17.2) than patients with few or no lymphocytic infiltrates (1.1±0.9; P < 0.001). The same is true for the number of GCs. In GD, the CXCR5 mRNA levels were not significantly different between patients without (7.0±2.6) and with (25.5±16.3) signs of Graves’ ophthalmopathy (GO) and between patients with long (>15 months; 13.7±5.9) or short (<5 months; 4.5±1.8) anti-thyroid drug treatment.

CXCR5 mRNA levels of tissues from GD patients with high numbers of lymphocytic infiltrates or GCs differed significantly from that of both tissues of TA patients (P < 0.01). CXCR5 mRNA levels were five times lower in autonomous nodules than in the corresponding quiescent tissue from TA patients.

**CXCL13 mRNA levels in thyroid tissues**

The two HT patients also showed the highest CXCL13 mRNA levels (zmol CXCL13 cDNA/PCR; 74.0 and 98.1). In GD, tissues with GC reactions have 10- to 20-fold transcription levels for CXCL13 compared with tissues without GCs. Tissues with high numbers of focal lymphocytic infiltrates (>5/226 mm²) showed ten times the CXCL13 mRNA level (mean±S.E.M. 17.5±5.5) compared with patients with no or low numbers of lymphocytic infiltrates (1.9±1.4; P < 0.001) or normal tissue from TA patients (1.8±0.7). CXCL13 mRNA levels differed significantly between autonomous single adenomas and the corresponding normal tissue (P < 0.005) from TA patients.

In GD patients, the CXCL13 mRNA level did correlate with the number of focal lymphocytic infiltrates and GCs, or with the level of TPO but not TBI antibodies for that matter (Table 2). The CXCL13 mRNA levels were not significantly different between GD patients without (9.6±4.7) and with (9.7±5.4) signs of GO and between GD patients with long (>15 months; 13.7±5.9) or short (<5 months; 4.5±1.8) anti-thyroid drug treatment.

**Flow cytometry**

PBLs differed from their thyroid-derived counterparts in terms of resting-state and lymph-node-homing capabilities, i.e. CD62L, CD45R0 and CCR7 expression. CD62L

---

**Figure 2** Quantification of CXCR5 and CXCL13 mRNA in thyroid tissues. Real-time PCR. (A) Amplification blot showing 10-fold dilutions of the standard for CXCR13 (1000–0.1 zmol CXCR13 cDNA/PCR). (B) Amplification blot showing the standard for CXCR13 cDNA as in (A), but typical Hashimoto’s thyroiditis (HT), Graves’ disease (GD), and thyroid autonomy (TA, nodule surrounding normal tissue) samples were added. (C, D) CXCL13 and CXCR5 cDNA quantification in thyroid tissues from HT patients, GD patients with a high (>5/226 mm²) or low number of focal lymphocytic infiltrates and in TA patients (normal and nodular tissue); means±S.E.M., *,**P < 0.005.
Table 2 Correlation of CXCL13 and CXCR5 mRNA levels with different parameters in patients with GD.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>CXCL13 mRNA</th>
<th>CXCR5 mRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of focal lymphocytic infiltrates</td>
<td>r = 0.678; P &lt; 0.005</td>
<td>r = 0.918; P &lt; 0.0005</td>
</tr>
<tr>
<td>Number of germinal centers CD18 mRNA</td>
<td>r = 0.630; P &lt; 0.005</td>
<td>r = 0.901; P &lt; 0.0005</td>
</tr>
<tr>
<td>Level of TPO autoantibodies</td>
<td>r = 0.695; P &lt; 0.002</td>
<td>r = 0.662; P &lt; 0.05</td>
</tr>
<tr>
<td>Level of TSH-R autoantibodies</td>
<td>r = 0.525; P &lt; 0.05</td>
<td>r = 0.482; P = 0.05</td>
</tr>
</tbody>
</table>

The percentage of lymphocytes expressing CXCR5 did not vary between normal subjects and patients with GD in peripheral blood. Comparing the percentage of CD3+ T-cells expressing CXCR5+ within TLs and PBLs, we found a significantly higher percentage within the thyroid. The percentage of CXCR5+ within the CD4+ T-cell fraction was doubled (Fig. 3). In the peripheral blood, only a minor population of CD3+CD8+ T-cells expressed the chemokine receptor. This percentage was increased within the thyroid (not shown).

Additionally, we compared the percentages of circulating and thyroid-derived memory CD4+ and CD8+ T-cells expressing CXCR5 (TFF cells). A significantly higher number of thyroid-derived CD4+ cells were positive for CD45RO and CXCR5 than the corresponding peripheral cells.

The percentage of CXCR5+ cells within peripheral and thyroid-derived CD19+ B-cells was equally high (Fig. 3). However, a small proportion of CD19+ thyroid-derived B-cells did not express the molecule. Also, the density of CXCR5 on peripheral B-cells was higher than on thyroid-derived B-cells.

Discussion

The chemokine receptor–ligand pair CXCR5 and CXCL13 is essential for the organization of lymphoid follicles in normal secondary lymphoid organs (1–3, 28). Here, we describe the correlation between CXCR5 and CXCL13 mRNA expression and the number of lymphocytic infiltrates and ectopic GCs in thyroid tissue affected by autoimmunity.

CXCR5 mRNA levels within thyroid tissues exclusively represent the extent of lymphocytic infiltration, and thus correlate with the number of lymphocytic infiltrates and GC as well as CD18 mRNA levels. Apart from CXCR5 mRNA quantification, we examined CXCR5 at the cellular level in flow cytometry. CXCR5+ T-cells constitute a minor fraction within peripheral blood memory CD4+ T-cells. These cells represent the pool of recent memory cells with a non-polarized phenotype and a recent history of immune activation (6, 29) and might play an immune surveillance function by disseminating ‘antigen-priming’ information from the origin-inflamed secondary (or ectopic?) lymphoid tissue to alternative tissues previously not involved (7). It is unknown whether this peripheral memory CD4+CXCR5+ T-cell pool is relatively constant or increases during intensified immune responses. We found no significant differences between GD patients and normal subjects regarding the percentage of these cells in the peripheral blood. In contrast, the percentage of memory CD4+CXCR5+ cells is significantly higher within thyroid-derived compared with peripheral T-lymphocytes from the same GD patient. In normal secondary lymphoid tissues, these cells possess three options for further development (6). First, the cells may be recruited into B-cell follicles which selectively express CXCL13 by means of CXCR5 expression. Here, the memory CD4+CXCR5+ cells efficiently support the production of immunoglobulins, thus characterized as TFF (8, 30). Secondly, if not recruited to the B-cell zone, the cells reside in the T-cell zone and differentiate into Th1 or Th2 cells but lose CXCR5. Thirdly, these CXCR5+ cells have the option of exiting the lymphoid tissue to form the peripheral pool of recent memory CD4+ T-cells as mentioned above. Whether memory CD4+CXCR5+ cells within ectopic thyroid follicles undergo the same development as in normal secondary follicles is unclear.

Our result revealing a higher percentage of CD3+CXCR5+ cells within the thyroid compared with the periphery differs from that of Armengol et al. (19), who did not find any difference between the two
compartments. We isolated TLs mechanically, whereas Armengol et al. digested thyroid tissue enzymatically. That group itself showed modulation of surface receptors after digestion. We demonstrated that some of the chemokine receptors were unfavorably influenced by enzymatic separation procedures (18). We could dispel the suspicion that mechanically isolated lymphocytes might be PBLs since our TLs had lost expression of CD62L and CCR7 and typically contained a higher percentage of memory CD45R0+ cells compared with PBLs (31). Also, we could not confirm the result reached by Armengol et al. (19) that the percentage of circulating CCR7+ lymphocytes was significantly reduced in GD patients compared with controls.

Although CXCR5 is expressed on all peripheral B-cells in GD patients as in normal subjects (4), the percentage of thyroid-derived B-cells bearing CXCR5 was at nearly 90%. The small CD19-CXCR5+ B-cell population may represent plasma cells that downregulate CXCR5, while copious immunoglobulin synthesis and secretion is induced (32).

Our CXCL13 data confirm (i) results from Armengol et al. (19) of increased CXCL13 mRNA levels within thyroids with high numbers of lymphocytic infiltrates often forming lymphoid ectopic follicles and (ii) results from other non-lymphoid tissues containing these structures. In salivary gland tissue from Sjogren’s syndrome patients, CXCL13 was expressed within lymphoid aggregates that shared many structural features with normal GCs (11, 33). CXCL13 is produced and accumulated in irregular lymphoid aggregates in ulcerative colitis lesions (12) and in Helicobacter pylori-induced, mucosal-associated lymphoid tissue and gastric lymphoma (34). CXCL13 and tumor necrosis factor family member lymphotoxin-β are both strongly involved in GC formation, and have been described as predictors for the recruitment of follicular dendritic cells and the formations of GCs in rheumatoid arthritis (9, 10, 35). We found significant differences between nodules and surrounding tissue in TA thyroids regarding CXCR5 and CXCL13 mRNA levels. In most cases, only very few lymphocytes, if any, could be detected, and no CD18 mRNA could be measured within the nodules, which explains the usually negative results. However, we found slight basal CXCL13 mRNA expression in normal thyroid without focal lymphocytic infiltrates. Here, dendritic cells were relatively scarce (36). In addition to these rare cells, other cell types may contribute to the signal. Non-stimulated thyrocytes as well as thyroid-derived fibroblasts were CXCL13 mRNA-negative (not shown). However, stimulated cells as well as endothelial and C-cells were not examined for CXCL13 mRNA expression.

All these data suggest that constitutive chemokines like CXCL13 and their receptors not only contribute to lymphoid homing in normal tissues, but also play a critical role in the persistence of chronic lymphocytic infiltration and establishing GCs at unusual sites such...
as the thyroid. Here, by creating a local microenvironment supportive of focal B-cell aggregation and differ- entiation with structural features that are remarkably similar to GCs, CXCL13 and CXCR5 contribute to the production of TPO autoantibodies classically associated with GD. Our data confirmed the studies showing (i) selective binding of the two autoantigens TPO and thyroglobulin in the ectopic GCs, indicating that GC for- mation was committed to these self antigens (17), and (ii) a correlation between TPO antibodies and lymphocytic infiltration (37). When GD tissues were ana- lyzed and compared with TA thyroid tissues, TBIi antibodies correlated with CXCR5 and CXCL13 mRNA levels as shown for CXCL13 in the study of Armengol et al. (19). However, CXCR5 and CXCL13 mRNA levels were not related to TSH-R antibody for- mation within the group of GD patients, suggesting that B-cells producing these antibodies are not located in formatted structures such as local infiltrates or ecto- pic follicles or are partially located outside the thyroid. TBIi might not be produced exclusively by the thyroid itself. As shown in a short-term culture system, lymphocytes from cervical lymph node, thyroid and bone marrow contributed to thyroid autoantibody pro- duction (38). In the study by Chiuvato et al. (39), the disappearance of thyroid antibodies after surgical abla- tion of the thyroid was gradual and continued without any sharp decrease after the operation. This pattern of thyroid antibody disappearance suggests that extra- thyroidal tissues contribute to the production of thyroid antibodies, at least in long-standing autoimmune thyroid diseases. Memory cells within peripheral immune organs can be triggered to produce thyroid antibodies upon antigen stimulation (40). Furthermore, the first thyroid-draining lymph nodes during the development of intrathyroidal lymphoid tissue in BB-DP rats showed an early production of anti-thyroglobulin anti- bodies, which later switched to the thyroid when intrathyroidal lymphoid tissue occurred (41). Here, time and chronicity of the autoimmune process deter- mines the presence of extrathyroidal sites of autoanti- body synthesis. Moreover, microsomal (TPO) antibody titers seem to reflect the intensity of the intrathyroidal autoimmune process in GD better than TSH-R anti- bodies (37). The question is whether or not ectopic thyroid fol- licles mimic normal secondary lymphoid follicles in all aspects (19, 42). Here, we showed that the expression of CXCR5 and CXCL13 in autoimmune thyroids is remarkably similar to that in normal lymphoid tissues. Furthermore, as in normal lymph nodes, thyroid- derived lymphocytes lost the combination code for entry of T- and B-cells, the expression of CD62L and CCR7. However, the lack of concordance between rearrangements in CD20+ B-cells and plasma cells in rheumatoid synovium and the lack of identical rearrangements in adjacent B-cell clusters in Sjogren’s syndrome suggest that the GC-like structures seen in these autoimmune diseases mimic many, but not all of the functional features of classic GCs (42). Many of the necessary microenvironmental features required to generate functional GC-like structures exist in chronically inflamed non-lymphoid tissue, but not all of them are present: this might lead to the aberrant pro- duction of high-affinity antibodies with autoreactive properties. The question arises as to which factors ulti- mately control this process, as not all GD tissues showed high CXCL13 and CXCR5 mRNA levels or high numbers of lymphocytic infiltrates and GCs. Per- haps the different host response patterns suggest a probable contribution of genetic risk factors.

References